ImageneBio, Inc. Segments Disclosure
17. Segment Information
The Company operates and manages its business as a operating and reportable segment for the purpose of assessing performance and making operating decisions. The Company’s , who is the CODM, reviews the Company’s financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources. The CODM assesses operating performance as compared to planned activities for the operating segment and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations and comprehensive loss. The Company derives license revenue primarily in the United States from research
and development collaborations and manages the business activities on a consolidated basis. In addition, all segment assets are held in the United States.
In addition, the CODM is regularly provided the following significant segment financial information to assist in segment performance evaluation, resource allocation, and decision-making (in thousands):
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
|
$ |
800 |
|
|
$ |
3,500 |
|
|
Research and Development |
|
|
|
|
|
|
||
Clinical research and outside services |
|
$ |
13,752 |
|
|
$ |
12,666 |
|
Compensation and related |
|
|
4,403 |
|
|
|
4,001 |
|
Other research and development expenses(a) |
|
|
— |
|
|
|
15,442 |
|
Stock-based compensation expense |
|
|
10,370 |
|
|
|
— |
|
Total research and development expense |
|
$ |
28,525 |
|
|
$ |
32,109 |
|
General and Administrative |
|
|
|
|
|
|
||
Compensation and related |
|
|
5,182 |
|
|
|
2,645 |
|
Consulting and professional services |
|
|
6,335 |
|
|
|
3,152 |
|
Other general and administrative expenses(b) |
|
|
4,188 |
|
|
|
2,594 |
|
Stock-based compensation expense |
|
|
5,021 |
|
|
|
— |
|
Total general and administrative expense |
|
$ |
20,726 |
|
|
$ |
8,391 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 10, 2026 | Showing above |
| 2024 | Mar 6, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.